Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Mueller

Showing results (81-90 of 220) with videos related to

Pageof 22
Sort By:
Hematological Oncology|June 5, 2018
Adverse outcome of AML with aberrant CD16 and CD56 NK cell marker expressionAlexandra Junge, Ulrike Bacher, Beatrice U Mueller, et al.
Oncogene|December 8, 2009
PU.1 is regulated by NF-kappaB through a novel binding site in a 17 kb upstream enhancer elementN Bonadies, Ch Neururer, A Steege, et al.
Journal of Tissue Viability|November 30, 2018
Dry skin in home care: A representative prevalence studyA Lichterfeld-Kottner, N Lahmann, U Blume-Peytavi, et al.
Haematologica|July 7, 2018
MDM2- and FLT3-inhibitors in the treatment of <i>FLT3</i>-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurinKatja Seipel, Miguel A T Marques, Corinne Sidler, et al.
Journal of Cellular and Molecular Medicine|August 8, 2009
Unfolded protein response suppresses CEBPA by induction of calreticulin in acute myeloid leukaemiaJulian A Schardt, Marianne Eyholzer, Nikolai A Timchenko, et al.
British Journal of Cancer|June 1, 2006
Mutations of the transcription factor PU.1 are not associated with acute lymphoblastic leukaemiaB U Mueller, T Pabst, P Hauser, et al.
Pediatric Blood & Cancer|April 14, 2011
Translating scientific advances to improved outcomes for children with sickle cell disease: a timely opportunityJean L Raphael, Patricia L Kavanagh, C Jason Wang, et al.
International Archives of Allergy and Applied Immunology|January 1, 1982
Studies of chemically modified honeybee venom. I. Biochemical, toxicologic and immunologic characterizationU Mueller, R Reisman, W Elliott, et al.
Acta Crystallographica. Section F, Structural Biology and Crystallization Communications|May 23, 2013
Expression, purification, crystallization and preliminary X-ray structure analysis of wild-type and L(M196)H-mutant Rhodobacter sphaeroides reaction centresA G Gabdulkhakov, T Y Fufina, L G Vasilieva, et al.
Pediatric Blood & Cancer|July 16, 2008
A critical assessment of transcranial doppler screening rates in a large pediatric sickle cell center: opportunities to improve healthcare qualityJean L Raphael, Priya B Shetty, Hao Liu, et al.
Pageof 22

Showing results (81-90 of 220) with videos related to

Sort By:
Pageof 22
Hematological Oncology|June 5, 2018
Adverse outcome of AML with aberrant CD16 and CD56 NK cell marker expressionAlexandra Junge, Ulrike Bacher, Beatrice U Mueller, et al.
Oncogene|December 8, 2009
PU.1 is regulated by NF-kappaB through a novel binding site in a 17 kb upstream enhancer elementN Bonadies, Ch Neururer, A Steege, et al.
Journal of Tissue Viability|November 30, 2018
Dry skin in home care: A representative prevalence studyA Lichterfeld-Kottner, N Lahmann, U Blume-Peytavi, et al.
Haematologica|July 7, 2018
MDM2- and FLT3-inhibitors in the treatment of <i>FLT3</i>-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurinKatja Seipel, Miguel A T Marques, Corinne Sidler, et al.
Journal of Cellular and Molecular Medicine|August 8, 2009
Unfolded protein response suppresses CEBPA by induction of calreticulin in acute myeloid leukaemiaJulian A Schardt, Marianne Eyholzer, Nikolai A Timchenko, et al.
British Journal of Cancer|June 1, 2006
Mutations of the transcription factor PU.1 are not associated with acute lymphoblastic leukaemiaB U Mueller, T Pabst, P Hauser, et al.
Pediatric Blood & Cancer|April 14, 2011
Translating scientific advances to improved outcomes for children with sickle cell disease: a timely opportunityJean L Raphael, Patricia L Kavanagh, C Jason Wang, et al.
International Archives of Allergy and Applied Immunology|January 1, 1982
Studies of chemically modified honeybee venom. I. Biochemical, toxicologic and immunologic characterizationU Mueller, R Reisman, W Elliott, et al.
Acta Crystallographica. Section F, Structural Biology and Crystallization Communications|May 23, 2013
Expression, purification, crystallization and preliminary X-ray structure analysis of wild-type and L(M196)H-mutant Rhodobacter sphaeroides reaction centresA G Gabdulkhakov, T Y Fufina, L G Vasilieva, et al.
Pediatric Blood & Cancer|July 16, 2008
A critical assessment of transcranial doppler screening rates in a large pediatric sickle cell center: opportunities to improve healthcare qualityJean L Raphael, Priya B Shetty, Hao Liu, et al.
Pageof 22